FINNENCE ▪ THE WIRE FILE
THE WIRE · № 64424
News▲ Bullish
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
KINDNews
DIRECTION▲ Bullish
SOURCES2
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 04:30 UTC
LAST UPDATE2026-10-05 04:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Advancing a rare-disease therapy into Phase 3 raises the developer's probability of eventual approval and value.
Rare-disease trial progress lifts small biotech prospects
CATALYST TO WATCH
Phase 3 enrollment and data readouts
MAIN RISK
Phase 3 failure or enrollment delays
FULL DISPATCH
The only known investigational therapy for SBMA in Phase 3 development worldwide AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) Following submission of the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
AFFECTEDSPDR Biotech ETF · XBI
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers2026-10-05 04:46 UTC
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers2026-10-05 04:46 UTC
→CORRELATIONshares Healthcare
Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights2026-10-05 05:38 UTC
Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights2026-10-05 05:38 UTC
←CORRELATIONshares Healthcare
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 20262026-10-04 03:09 UTC
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 20262026-10-04 03:09 UTC
←CORRELATIONshares Healthcare
Sandoz Agrees to $400 Million Deal to Resolve States’ Generic-Drug Antitrust Case2026-10-04 15:40 UTC
Sandoz Agrees to $400 Million Deal to Resolve States’ Generic-Drug Antitrust Case2026-10-04 15:40 UTC
←CORRELATIONshares Healthcare
Late-Breaking Clinical Trial Results Announced at The VEINS 20262026-10-04 21:16 UTC
Late-Breaking Clinical Trial Results Announced at The VEINS 20262026-10-04 21:16 UTC
←CORRELATIONshares Healthcare
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases2026-10-04 21:42 UTC
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases2026-10-04 21:42 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.